Inactive Instrument

Aytu Bioscience Inc Stock OTC Bulletin Board

Equities

AYTU

US0547542052

Pharmaceuticals

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Aytu Bioscience Inc
Sales 2024 * 81.33M 111M Sales 2025 * 78.22M 107M Capitalization 16.72M 22.87M
Net income 2024 * -13M -17.78M Net income 2025 * 3M 4.1M EV / Sales 2024 * 0.21 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.21 x
P/E ratio 2024 *
-1.12 x
P/E ratio 2025 *
4.31 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.67%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 49 15-04-15
Founder 49 15-04-15
Director of Finance/CFO 55 22-01-16
Members of the board TitleAgeSince
Director/Board Member 62 22-06-30
Founder 49 15-04-15
Chief Executive Officer 49 15-04-15
More insiders
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
More about the company